Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling.

BACKGROUND The acute management of acquired von Willebrand syndrome (AVWS) is aimed at achieving hemostasis with von Willebrand factor replacement, counteracting the pathologic antibodies with intravenous immunoglobulin (IVIG), and supportive care with blood transfusions. However, strategies for the long-term management of AVWS are not described, resulting… (More)